David Grob

David Grob's AcademicInfluence.com Rankings

David Grob

Medical

#1633

World Rank

#1994

Historical Rank

Toxicology

#19

World Rank

#21

Historical Rank

medical Degrees

David Grob

Philosophy

#4969

World Rank

#7658

Historical Rank

Logic

#2321

World Rank

#3291

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is David Grob Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David Grob's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Poisoning due to organophosphate insecticides. Acute and chronic manifestations. (1971) (604)
Lifetime course of myasthenia gravis (2008) (522)
The Course of Myasthenia Gravis and Therapies Affecting Outcome a (1987) (318)
Vincristine treatment of advanced cancer: a cooperative study of 392 cases. (1973) (228)
Electrocardiographic Changes and Myocardial Damage in Patients with Acute Cerebrovascular Accidents (1977) (200)
Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate). (1958) (175)
THE NATURAL COURSE OF MYASTHENIA GRAVIS AND EFFECT OF THERAPEUTIC MEASURES (1981) (171)
MYASTHENIA GRAVIS IN PATIENTS WITH THYMOMA, WITH PARTICULAR REFERENCE TO ONSET AFTER THYMECTOMY (1978) (168)
The effects and treatment of nerve gas poisoning. (1953) (155)
Neonatal myasthenia gravis: report of two cases and review of the literature. (1970) (148)
The manifestations and treatment of poisoning due to nerve gas and other organic phosphate anticholinesterase compounds. (1956) (148)
Staining for nerve fiber and cholinesterase activity in fresh frozen sections. (1967) (136)
Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes. (1961) (127)
High-dose intravenous immunoglobulin in the management of myasthenia gravis. (1986) (118)
Treatment of myasthenia gravis by immunoadsorption of plasma (1995) (116)
Course and management of myasthenia gravis. (1953) (102)
High-dose intravenous methylprednisolone in myasthenia gravis. (1985) (98)
Potassium movement in patients with familial periodic paralysis: relationship to the defect in muscle function. (1957) (86)
Familial myasthenia gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families. (1971) (82)
Use of oximes in the treatment of intoxication by anticholin-esterase compounds in normal subjects. (1958) (82)
Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis. (1994) (81)
Rhabdomyolysis related to cocaine abuse. (1988) (78)
Potassium movement in normal subjects: effect on muscle function. (1957) (76)
Transfusion-associated-graft-vs-host disease in a presumed immunocompetent patient. (1988) (73)
Corticosteroids in management of severe, generalized myasthenia gravis (1972) (71)
Chronic proximal spinal muscular atrophy. (1970) (70)
The administration of di-isopropyl fluorophosphate (DFP) to man; effect on plasma and erythrocyte cholinesterase; general systemic effects; use in study of hepatic function and erythropoiesis; and some properties of plasma cholinesterase. (1947) (70)
Anticholinesterase Intoxication in Man and its Treatment (1963) (67)
Failure of neuromuscular transmission and contractility during muscle fatigue (1984) (66)
Myasthenia gravis: current status of pathogenesis, clinical manifestations, and management. (1958) (66)
Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. (1988) (65)
Proteolytic enzymes; further studies on protein, polypeptide, and other inhibitors of serum proteinase, leucoproteinase, trypsin, and papain. (1949) (64)
The toxic effects in man of the anticholinesterase insecticide parathion (p-nitrophenyl diethyl thionophosphate). (1950) (62)
Idiopathic giant cell polymyositis. Report of a case and review of the syndrome. (1974) (61)
Ophthalmoplegia, ptosis, and miosis in temporal arteritis (1980) (60)
CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). XI. THE TREATMENT OF ACUTE MERCURY POISONING BY BAL. (1946) (58)
CORTICOTROPIN AND CORTICOSTEROIDS IN GENERALIZED MYASTHENIA GRAVIS: COMPARATIVE STUDIES AND ROLE IN MANAGEMENT (1976) (57)
Myasthenia gravis. A review of pathogenesis and treatment. (1961) (55)
The administration of di-isopropyl fluorophosphate (DFP) to man; effect on the central nervous system with special reference to the electrical activity of the brain. (1947) (50)
Malathion poisoning. A fatal case with cardiac manifestations. (1970) (48)
Corticotropin in generalized myasthenia gravis. Effect of short, intensive courses. (1966) (46)
THE ANTIPROTEOLYTIC ACTIVITY OF SERUM: I. THE NATURE AND EXPERIMENTAL VARIATION OF THE ANTIPROTEOLYTIC ACTIVITY OF SERUM (1943) (46)
Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration. (1952) (43)
Chondrodystrophic myotonia: report of two cases. Myotonia, dwarfism, diffuse bone disease, and unusual ocular and facial abnormalities. (1970) (43)
Studies in neuromuscular function. II. Effects of nerve stimulation in normal subjects and in patients with myasthenia gravis. (1956) (41)
Skeletal muscle fatigue and physical endurance of young and old mice (1998) (41)
CHARACTERISTICS AND MECHANISM OF NEURO‐MUSCULAR BLOCK IN MYASTHENIA GRAVIS (1976) (39)
Further Observations on the Effects of Autonomic Blocking Agents in Patients with Hypertension: II. Hemodynamic, Ballistocardiographic and Electrocardiographic Effects of Hexamethonium and Pentamethonium (1953) (38)
Death due to parathion, an anticholinesterase insecticide. (1949) (37)
Association of myasthenia gravis with pemphigus vulgaris, Candida albicans infection, polymyositis and myocarditis. (1973) (37)
Adverse Cardiovascular Effects of Anticholinesterase Medications (1987) (35)
Use of oximes in the treatment of intoxication by anticholinesterase compounds in patients with myasthenia gravis. (1958) (34)
Responses of intercostal muscle biopsies from normal subjects and patients with myasthenia gravis (1990) (34)
CHOLINESTERASE ACTIVITY OF THE MOTOR ENDPLATE IN ISOLATED MUSCLE MEMBRANE (1968) (34)
Treatment of anticholinesterase intoxication with oximes; use in normal subjects and in patients with myasthenia gravis. (1958) (34)
Production and role of cytokines in the CNS of mice with acute viral encephalomyelitis (1996) (33)
Studies on the folic acid vitamins. I. Observations on the metabolism of folic acid in man and on the effect of aminopterin (1958) (33)
Rhabdomyolysis and Myoglobinuric Acute Renal Failure Associated With Classic Heat Stroke (1995) (32)
Mechanisms of fatigue in normal intercostal muscle and muscle from patients with myasthenia gravis (1993) (31)
On the antithrombic and antiproteolytic activity of alpha tocopheryl phosphate. (1948) (31)
The effect of corticotropin on the neuromuscular junction (1968) (30)
Hypersensitivity to molybdenum as a possible trigger of ANA-negative systemic lupus erythematosus. (1994) (30)
THE USE OF ACTH AND CORTICOSTEROIDS IN MYASTHENIA GRAVIS (1971) (29)
On certain vascular effects of curare in man: the histamine reaction. (1947) (29)
Immune responses, and autoimmune outcome, during virus infection of the central nervous system. (1994) (28)
Abnormalities in neuromuscular transmission, with special reference to myasthenia gravis. (1953) (28)
Effect of serum and serum globulin of patients with myasthenia gravis on neuromuscular transmission (1969) (28)
Proteolytic enzymes; the control of their activity. (1946) (28)
Studies in neuromuscular function. IV. Stimulating and depressant effects of acetylcholine and choline in patients with myasthenia gravis, and their relationship to the defect in neuromuscular transmission. (1956) (28)
Conduction velocity in the ulnar nerve in hemiplegic patients. (1971) (26)
Diclofenac-induced rhabdomyolysis (1996) (26)
Influenza virus vaccination of patients with multiple sclerosis (1997) (26)
Diffuse myopathy related to meperidine addiction in a mother and daughter. (1968) (26)
AUTOANTIBODIES AND MYASTHENIA GRAVIS, WITH SPECIAL REFERENCE TO MUSCLE RIBONUCLEOPROTEIN * (1966) (25)
Corticotrophin therapy in myasthenia gravis (1971) (25)
Studies in neuromuscular function. V. Effects of anticholinesterase compounds, d-tubocurarine, and decamethonium in normal subjects. (1956) (24)
Studies in neuromuscular function. I. Introduction and methods. (1956) (23)
Studies in neuromuscular function. III. Stimulating and depressant effects of acetylcholine and choline in normal subjects. (1956) (22)
ALTERATIONS IN REACTIVITY TO ACETYLCHOLINE IN MYASTHENIA GRAVIS AND CARCINOMATOUS MYOPATHY * (1966) (22)
Pharmacology and toxicology of certain organic phosphorus insecticides; general description of their activity and usefulness; pharmacology; toxicology; clinical experience; effects on beneficial forms of life, crops and soil and residue hazards. (1950) (21)
THE ROLE OF HUMORAL AND CELLULAR IMMUNE FACTORS IN NEUROMUSCULAR BLOCK IN MYASTHENIA GRAVIS (1976) (21)
Effect of Cleistanthus collinus leaf extract on neuromuscular function of the isolated mouse phrenic nerve-diaphragm. (1989) (21)
Effect of ethanol on function of the rat heart and skeletal muscles. (1995) (20)
Effect of cocaine on leakage of creatine kinase from isolated fast and slow muscles of rat. (1993) (20)
Treatment of anticholinesterase intoxication with oximes (1958) (20)
Case report: diclofenac-induced rhabdomyolysis. (1996) (19)
Diclofenac-lnduced Rhabdomyolysis (1996) (19)
Role of the immune response in Sindbis virus-induced paralysis of SJL/J mice. (1989) (19)
Alterations in neuromuscular transmission in myasthenia gravis as determined by studies of drug action. (1955) (19)
Complement fixing and tissue binding serum globulins in patients with myasthenia gravis, and their relation to muscle ribonucleoprotein. (1967) (19)
Phenotypic and functional characterization of T cells from patients with myasthenia gravis. (1990) (19)
Needlestick injury: blood, mononuclear cells, and acquired immunodeficiency syndrome. (1992) (18)
Myasthenia gravis occurring in twins (1971) (18)
Further Observations on the Effects of Autonomic Blocking Agents in Patients with Hypertension: I. General Systemic Effects of Hexamethonium, Pentamethonium, and Hydrazinophthalazine (1953) (18)
Effect of alcohol and electrical stimulation on leakage of creatine kinase from isolated fast and slow muscles of rat. (1995) (18)
CHOLINERGIC RECEPTORS IN SKELETAL MUSCLE: ISOLATION AND PROPERTIES OF MUSCLE RIBONUCLEOPROTEIN WITH AFFINITY FOR d‐TUBOCURARINE AND ACETYLCHOLINE, AND BINDING ACTIVITY OF THE SUBNEURAL APPARATUS OF MOTOR END PLATES WITH DIVALENT METAL IONS * (1967) (18)
Electromyographic changes in myasthenia gravis. (1955) (18)
Effect on mice of intravenous administration of lymphocytes from normal subjects and from patients with myasthenia gravis (1969) (18)
Rhabdomyolysis and drug-related myopathies. (1990) (18)
Studies in neuromuscular function. VI. Effects of anticholinesterase compounds, d-tubocurarine, and decamethonium in patients with myasthenia gravis. (1956) (17)
SPONTANEOUS END‐PLATE ACTIVITY IN NORMAL SUBJECTS AND IN PATIENTS WITH MYASTHENIA GRAVIS * (1971) (17)
Metabolic diseases of muscle. (1963) (17)
THE ANTIPROTEOLYTIC ACTIVITY OF SERUM : II. PHYSIOLOGICAL SIGNIFICANCE. THE INFLUENCE OF PURIFIED TRYPSIN INHIBITOR ON THE COAGULATION OF THE BLOOD. (1943) (16)
Production of anti-acetylcholine receptor-alpha antibody in vitro by peripheral blood lymphocytes of patients with myasthenia gravis: role of immunoregulatory T cells and monocytes. (1994) (16)
Myasthenia gravis and hyperthyroidism occurring in two sisters (1971) (16)
Lymphocytes of patients with myasthenia gravis. Local effects in rats following intramuscular administration. (1969) (16)
Motor nerve endings in extraocular muscles (1968) (15)
Potassium and caffeine contractures of mouse muscles before and after fatiguing stimulation (1994) (15)
The administration of di-isopropyl fluorophosphate (DFP) to man; effect on intestinal motility and use in the treatment of abdominal distention. (1947) (15)
Cholinesterase activity of motor end plate in human skeletal muscle. (1970) (14)
Ribonucleoprotein in human skeletal muscle with affinity for d-tubocurarine and acetylcholine. (1967) (14)
The anticholinesterase activity in vitro of the insecticide parathion (p-nitrophenyl diethyl thionophosphate). (1950) (14)
Peripheral mechanisms of fatigue in muscles of normal and dystrophic mice (1991) (13)
Observations of the effects of the autonomic blocking agent, bis-trimethylammonium pentane dibromide (C5) in normal subjects and in patients with peripheral vascular disease and hypertension, and comparison with tetraethylammonium chloride. (1950) (13)
The administration of di-isopropyl fluorophosphate (DFP) to man. (1947) (13)
Chronic proximal spinal muscular atrophy abstract human (1969) (13)
Observations of the effects of tetraethyl pyrophosphate in man, and on its use in the treatment of myasthenia gravis. (1949) (13)
INTRODUCTION: MYASTHENIA GRAVIS IN PERSPECTIVE (1976) (13)
DESENSITIZATION TO ACETYLCHOLINE AT MOTOR END PLATES IN NORMAL HUMANS, PATIENTS WITH MYASTHENIA GRAVIS, AND EXPERIMENTAL MODELS OF MYASTHENIA GRAVIS (1981) (12)
Familial concurrence of myasthenia gravis and rheumatoid arthritis. (1970) (12)
Proteolytic enzymes; the physiological significance of the control of their activity, especially with respect to bacterial growth. (1946) (11)
Dantrolene sodium reduces the enhanced leakage of creatine kinase caused by ethanol, cocaine, and electrical stimulation in isolated fast and slow muscles of rat. (1997) (11)
MOTOR END PLATE REACTIVITY TO DIVALENT METAL IONS HISTOCHEMICAL STUDIES (1967) (10)
Myopathies and their relation to thyroid disease. (1963) (10)
An electromyographic study of a spinal cord reflex in the normal human arm. (1957) (10)
Manifestations and treatment of nerve gas poisoning in man. (1956) (10)
The effects of bis-trimethylammonium decane diiodide and dibromide on neuromuscular function and on induced convulsions in man. (1949) (9)
Corticotropin therapy and thymectomy in management of myasthenia gravis. (1971) (9)
Urinary incontinence following prostatectomy in patients with myasthenia gravis. (1982) (9)
Antibodies against myofibrillar proteins in myasthenia gravis patients. (1992) (9)
Effect of cocaine on responses of mouse phrenic nerve-diaphragm preparation. (1991) (9)
Neuromuscular transmission in neonatal mice injected with serum globulin of myasthenia gravis patients (1982) (8)
Myasthenia gravis. Serum globulin bound in vivo to skeletal muscle striations. (1967) (8)
The renal excretion of histamine and histidine in man, and the effect of adrenocorticotropic hormone (ACTH) and cortisone administration. (1952) (7)
Characterization of in vivo-activated T cell clones from peripheral blood of multiple sclerosis patients. (1991) (7)
INTRODUCTION MYASTHENIA GRAVIS‐RETROSPECT AND PROSPECT (1981) (7)
Some ocular effects of a new anticholinesterase agent; tetraethyl pyrophosphate and its use in the treatment of chronic glaucoma. (1950) (7)
ON CERTAIN EFFECTS OF ALPHA‐TOCOPHERYL PHOSPHATE ON OXIDATIVE MECHANISMS OF STRIATED MUSCLE (1949) (6)
Myasthenia gravis: pathophysiology and management. (1981) (6)
Inhibition of Ehrlich ascites tumour cells by skeletal muscle extracts. (1968) (6)
THE ANTIPROTEOLYTIC ACTIVITY OF SERUM : III. PHYSIOLOGICAL SIGNIFICANCE. THE INFLUENCE OF TRYPSIN AND OF ANTIPROTEASE ON BACTERIAL GROWTH AND SULFONAMIDE ACTION (1943) (6)
Management of the patient with primary "essential" hypertension. (1955) (5)
Cause of Weakness in Myasthenia Gravis (1976) (5)
Therapy of Myasthenia Gravis (1963) (5)
Acute neuromuscular disorders. (1981) (4)
THE ANTIPROTEOLYTIC ACTIVITY OF SERUM (1943) (4)
THE ANTIPROTEOLYTIC ACTIVITY OF SERUM (1943) (4)
Effect of antibodies against skeletal muscle constituents on muscle function in rats. (1969) (4)
The effect of adrenocorticotropic hormone administration on skin, conjunctival, and nasal mucous membrane reactivity to histamine and antigens in man. (1952) (3)
A simple clamp for skeletal muscle biopsy. (1968) (3)
Pharmacology and Toxicology of certain Organic Phosphorus Insecticides. Report from the Committee on Pesticides to the Council on Pharmacy and Chemistry. (1950) (3)
Production of Interferon Gamma and Interleukin‐2 by Peripheral Blood Lymphocytes of Patients with Myasthenia Gravis and Other Autoimmune Diseases a (1993) (3)
Mechanisms of Fatigue in Normal Young and Old Mice (1998) (3)
Some Preliminary Observations on the Neuromuscular and Ganglionic Blocking Action in Man of Bis-Trimethylammonium Decane and Pentane Diiodide. (1948) (3)
Presence of cross-reactive antibodies to HTLV-1 and absence of antigens in patients with multiple sclerosis. (1993) (3)
Myasthenia gravis: effect of the serum and serum globulin on neuromuscular transmission. (1968) (3)
Use of drugs in myopathies. (1976) (3)
Muscular disease. (1961) (2)
Side effects after treatment with nitrofurantoin. (1977) (2)
Corticotropin therapy and thymectomy in management of severe, generalized myasthenia gravis. (1970) (2)
The use of bis-trimethylammonium decane dibromide in anesthesia. (1949) (2)
472 – CORTICOTROPIN AND CORTICOSTEROIDS IN THE MANAGEMENT OF MYASTHENIA GRAVIS (1977) (2)
Detection of HIV antibody and antigen (p24) in residual blood on needles and glass. (1990) (2)
Use of Corticoid in the Management of Severe Generalized Myasthenia Gravis and Comparison with Corticotropin. (1971) (2)
Inhibition of growth of mouse ehrlich ascites by normal tissue extracts. (1978) (2)
Corticotropin therapy in myasthenia gravis: indications and limitations. (1970) (2)
Detection of HIV Antibody and Antigen (p24) in Residual Blood on Needles and Glass (1990) (2)
The diagnosis and management of disorders of muscle function. (1955) (2)
Enzyme inhibition by alpha-tocopherol phosphate: Effect on certain respiratory and proteolytic systems and on blood coagulation (1948) (1)
The biochemistry of myasthenia gravis and muscular dystrophy. Edited by G. G. Lunt and R. M. Marchbanks, 373 pp, illus, Academic Prcrss, London, 1978. $24.88 (1979) (1)
Dissemination of Walker 256 carcinoma cells to rat skeletal muscle (1986) (1)
Some preliminary observations on the neuromuscular and ganglionic blocking action in man of bis-trimethylammonium decane and petane dirodide. (1949) (1)
Observations on the nature of the neuromuscular block in myasthenia gravis. (1954) (1)
C – Neuromuscular Blocking Drugs* (1967) (1)
Diagnosis and management of the curable forms of hypertension. (1960) (1)
Giant cell arteritis presenting as painful third nerve palsy with normal erythrocyte sedimentation rate (2006) (0)
PS-4-8 Spontaneous motor activity and physical endurance of young and old mice (1995) (0)
Memorandum from David Grob to Fred Grubel [on purchase of internal pacemakers for implantation in patients] (1962) (0)
THE ANTIPROTEOLYTIC ACTIVITY OF SERUM (1943) (0)
Newer Aspects of Neuromuscular Disease. (1966) (0)
Myasthenia gravis-retrospect and prospect. (1981) (0)
HUMAN MOTOR END‐PLATE CHOLINESTERASE ACTIVITY AND THE EFFECT OF ANTICHOLINESTERASE COMPOUNDS (1981) (0)
Effect of cocaine on function of rat heart and skeletal muscle (1992) (0)
Effect of anti-hypertensive drugs on renal blood flow and function. (1955) (0)
MYASTHENIA gravis; diagnosis, treatment and management. (1957) (0)
PROTEOLYTIC ENZYMES (1946) (0)
[Neutral therapy]. (1952) (0)
Pharmacology in Clinical Practice. Harry Beckman. Philadelphia-London: Saunders, 1952. 839 pp. Illus. $12.50 (1953) (0)
Conduction velocity of ulnar nerve in hemiplegic patients. (1969) (0)
Procainamide hydrochloride sensitivity. Manifested by fever and chills. (1973) (0)
Compound action potential and tension during fatigue of skeletal muscles (1983) (0)
376 – HUMAN MOTOR ENUPLATE CHOLINESTERASE: INHIBITION BY ANTICHOLINESTERASE COMPOUNDS USED FOR MANAGEMENT OF MYASTHENIA GRAVIS (1978) (0)
PANEL DISCUSSION (1971) (0)
Individual and combined effects of cafeine and nicotine on responses of the isolated rat heart (1996) (0)
Pharmacology in Clinical Practice . Harry Beckman. Philadelphia-London: Saunders, 1952. 839 pp. Illus. $12.50. (1953) (0)
Dexamethasone dosage suggested every 3–4 days in myasthenia gravis (1977) (0)
Editorial: Cause of weakness in myasthenia gravis. (1976) (0)
Reserpine (serpasil) and other alkaloids of Rauwolfia serpentina: Chemistry, pharmacology, and clinical applications (1955) (0)
Primary Care vs Principal Care (1980) (0)
PROTEOLYTIC ENZYMES (1949) (0)
Observations on the nature of the neuromuscular block in myasthenia gravis. (1955) (0)
THE ANTIPROTEOLYTIC ACTIVITY OF SERUM I. THE NATURE AND EXPE~TM-F.NTAL VARIATION OF THE ANTIPROTEOLYTIC (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David Grob?

David Grob is affiliated with the following schools:

Johns Hopkins University

David Grob's Academic­Influence.com Rankings

Why Is David Grob Influential?

David Grob's Published Works

Published Works

What Schools Are Affiliated With David Grob?

David Grob's AcademicInfluence.com Rankings